Microarray analysis of self-reactive plasma cells (PCs), which are a hallmark of autoimmune diseases, isolated from scleroderma patients and compared to those of healthy donors.
The samples for this study were obtained from the MI-CP200, Phase 1, randomized, double-blind, placebo-controlled study for evaluation of the safety and tolerability of escalating single IV doses of MEDI-551 in adult subjects with scleroderma.
In the comparison, only samples of scleroderma patients prior to treatment were compared to normal controls.